Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ajinomoto plans expansion of feed amino Acids capacity
The company intends to increase L-Lysine production capacity by 150 kilo metric tonne (KMT), L-Threonine by 80 KMT, and L-Tryptophan by 7 KMT. Feed-use amino acid products will
The company intends to increase L-Lysine production capacity by 150 kilo metric tonne (KMT), L-Threonine by 80 KMT, and L-Tryptophan by 7 KMT. Feed-use amino acid products will
AM-831 drug combines muscarinic m1 partial agonism with both dopamine D2 and serotonin 5-HT2A antagonism. The Phase I study is intended to evaluate the safety, tolerability and pharmacokinetics
Plenadren, an oral once daily tablet, is a dual release hydrocortisone replacement therapy. The move follows the satisfactory opinion adopted by the Committee for Medicinal Products for Human
New investors include GE, BioMed Ventures and Henri Termeer, former Chairman and CEO of Genzyme Corporation. According to the company, the financing will be used to continue the
Cimzia is a PEGylated anti-TNF (Tumor Necrosis Factor), having high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. The data suggested that disease activity response
DEB025 belongs to a new class of drugs called cyclophilin inhibitors and offers an effective treatment option across HCV genotypes, with a high barrier to resistance. The 12-week
PatientKeeper’s clinical applications provides a physician-friendly interface and allows voluntary physician adoption of healthcare IT required for meaningful use compliance. Conway will install PatientKeeper’s CPOE (Computerised Physician Order
As per the deal, Astra Zeneca lab will choose between 250 anticancer drugs that will be produced in Algeria, bernama.com.my reported. The agreement will be signed by end
The technology, HyACT, is said to improve the delivery of chemotherapy drugs to site of tumours, including HA-irinotecan, which combines with Pfizer’s Camptosar for the treatment of colon
According to the company, in January 2012, the facility for Cyprotex’s US operations will be increased from 4,400 sq ft to 8,200 sq ft in order to meet